Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019.
Titilope OlanipekunCharles RitchieTemidayo AbeValery EffoeAbimbola Chris-OlaiyaIsaac BineyYoung M ErbenPramod GuruDevang SanghaviPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023)
Inferior vena cava filters (IVCF) are associated with medical complications. The 2010 and 2014 FDA safety warnings appeared to have synergistically contributed to a significant decline in IVCF utilization rates from 2010 - 2019 in the US. IVC filter placements in patients without venous thromboembolism (VTE) declined at a higher rate than VTE. However, IVCF utilization varied across hospitals and geographical locations, likely due to the absence of universally accepted clinical guidelines on IVCF indications and use. Harmonization of IVCF placement guidelines is needed to standardize clinical practice, thereby reducing the observed regional and hospital variations and potential IVC filter overutilization.
Keyphrases
- inferior vena cava
- venous thromboembolism
- clinical practice
- pulmonary embolism
- vena cava
- direct oral anticoagulants
- healthcare
- end stage renal disease
- drug administration
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- human health
- emergency department
- patient reported outcomes
- risk factors
- climate change